What Are the Prescription Drug Provisions in the Inflation Reduction Act?
This slideshow explains the prescription drug provisions proposed in the Inflation Reduction Act as passed by the Senate
View the Latest: Prescription Drugs
Filter
-
-
Health Care Inflation in the U.S.
Event Date:EventThe pressures of inflation are far reaching, affecting providers, insurers, government programs such as Medicaid and Medicare, and, ultimately, the American people. Over the coming months, health care providers and insurers will wrap up pricing negotiations and set premiums for the next year. Amid these negotiations, there remain big questions as to how economic policy and legislation such as the Inflation Reduction Act will influence pricing and payment for insurance and health care, including prescription…
-
The Inflation Reduction Act is a Foot in the Door for Containing Health Care Costs
PerspectiveIn this column for the JAMA Forum, KFF's Larry Levitt explores the Medicare drug-price negotiation provisions and other significant drug-price changes in the Inflation Reduction Act and their potential to lead to further efforts to address health care costs.
-
Abortion Grows as a Motivator for Midterm Voters, Particularly for Democrats and in States Where It Has Become Illegal Since the Supreme Court Overturned Roe v. Wade
News ReleaseFew Voters Know About the Medicare Drug Provisions in the Inflation Reduction Act, Though Seniors are More Aware and Would Be Likely to Vote for Candidates Who Support Them About a month ahead of the 2022 midterm election, abortion continues to grow as a motivating issue for voters, especially among Democrats and those living in states where abortion is now illegal, the latest KFF Health Tracking Poll finds. Half (50%) of voters now say the…
-
KFF Health Tracking Poll – March 2022: Economic Concerns and Health Policy, The ACA, and Views of Long-term Care Facilities
FeatureThis poll finds the public's health care priorities for Congress focus on reducing out-of-pocket costs, and concerns over inflation and the economy are top of mind as voters begin to think about the November midterm elections. The poll also examines views of the ACA and nursing homes.
-
New KFF Brief Takes a Closer Look at “Tele-PrEP” and the Future of PrEP Services in the United States
News ReleaseIn 2020, only 25% of people who could benefit from pre-exposure prophylaxis (PrEP), a medication that reduces the risk of acquiring HIV, were prescribed it. Using telehealth to provide PrEP, “tele-PrEP,” is a new approach that shows potential for expanding access to PrEP use in the United States that predates the COVID-19 pandemic. A new KFF analysis takes a deep dive into the tele-PrEP landscape, from the types of providers offering the service to the…
-
Potential Implications of Policy Changes in Medicaid Drug Purchasing
Issue BriefThis brief examines how leading federal and state policy options related to changes in Medicaid Drug Rebate Program (MDRP), drug pricing, and payment and management of the Medicaid prescription drug would affect state and federal governments as well as private industry (including drug manufacturers, managed care organizations, and pharmacies).
-
A New Analysis Takes a Closer Look at Online Contraception Platforms Amid the Pandemic
News ReleaseEven prior to the COVID-19 pandemic, hormonal contraception became more accessible to many outside of traditional clinical settings through websites or apps that offer contraception via telehealth. To better understand this emerging method of contraceptive access, a new KFF analysis provides a deeper look at telecontraception platforms, offering insights into the practices of 13 different companies based on information collected between November 2020 through January 2021. Key highlights from the report include: All of the…
-
Medicare’s Coverage Decision for the New Alzheimer’s Drug and Why It Matters
Policy WatchThis policy watch discusses the implications of Medicare's preliminary National Coverage Determination for the new Alzheimer's drug, Aduhelm, on the 2022 Medicare Part B premium and the possibility of an adjustment based on the coverage decision. The piece also discusses the implications for Medicare spending and the connection to ongoing policy discussions around prescription drug proposals in the Build Back Better Act.
-
Why Medicare’s Aduhelm Coverage Decision Could Increase Pressure on Officials to Roll Back the Record Part B Premium Increase for 2022
News ReleaseIn a new Policy Watch, KFF experts explain why Medicare’s preliminary decision to cover a new Alzheimer’s drug only for a limited group of beneficiaries is likely to intensify pressure on officials to reconsider the increase in the Medicare Part B premium for 2022. Earlier this week, CMS issued a preliminary National Coverage Determination that would limit coverage of the new drug, Aduhelm, to beneficiaries with mild cognitive impairment who participate in approved clinical trials…